The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
-
The University of Alabama at Birmingham, Birmingham, Alabama, United States, 35294
Local Institution - 0179, Jasper, Alabama, United States, 35501-0102
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States, 85013-4220
Local Institution - 0396, La Jolla, California, United States, 92037-1027
Local Institution - 0112, La Jolla, California, United States, 92093
University of Southern California (USC) - Keck School of Medicine (KSOM) - Transplant Clinic, Los Angeles, California, United States, 90033-5313
David Geffen School of Medicine at UCLA, Los Angeles, California, United States, 90095-3075
UC Irvine Medical Center, Orange, California, United States, 92868-3201
University of California UC Davis Medical Center, Sacramento, California, United States, 95817
University of California, San Francisco Medical Center- Pulmonary Practice, San Francisco, California, United States, 94143-2202
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
40 Years to
ALL
No
Bristol-Myers Squibb,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2026-10-26